Michael Sarcone – Jefferies

Jefferies

A Jefferies analyst with 10 tracked ratings across 6 distinct tickers has a 3.2-star track record and a perfect 100% success rate on the captured sample, covering both specified sources.

Aggregated from multiple market-data sources

Total ratings

Tickers covered

Sources

Aggregated

Latest rating

3 months ago

2026-02-12 00:00:00+00

Track record

Aggregated

No track record data

Bullish: 3
Hold: 3
Bearish: 0

Aggregated

100% success rate

Bullish: 0
Hold: 4
Bearish: 0

Aggregated

Not available

Bullish: 3
Hold: 4
Bearish: 0

Recent ratings

Ticker	Date	Rating	Price target	Source
INSP	2026-02-12	hold	$66.00	Aggregated
AXGN	2026-01-22	buy	$40.00	Aggregated
INSP	2025-12-22	hold	-	Aggregated
AXGN	2025-12-04	buy	$36.00	Aggregated
GKOS	2025-11-13	buy	$130.00	Aggregated
ALGN	2025-10-10	hold	$140.00	Aggregated
XRAY	2025-10-10	hold	$13.00	Aggregated
PEN	2025-07-23	buy	$325.00	Aggregated
EDAP	2025-04-04	hold	$2.00	Aggregated
PRCT	2024-11-14	hold	$95.00	Aggregated
PRCTPROCEPT BIOROBOTICS CORP	2024-11-14	hold	$95.00	Aggregated
GKOSGLAUKOS CORPORATION	2024-05-06	unknown	$125.00	Aggregated
PROF	2023-03-21	unknown	$10.00	Aggregated
PROFPROFOUND MEDICAL CORP	2023-03-21	hold	$10.00	Aggregated
AXGN	2022-11-11	buy	$15.00	Aggregated
EDAP	2022-11-01	buy	$11.00	Aggregated
EDAPEDAP TMS S.A. - ADR	2022-11-01	unknown	$11.00	Aggregated

Tickers covered(13)

Ticker	Ratings	Last rating	Sources
INSP	2	2026-02-12	Aggregated
AXGN	3	2026-01-22	Aggregated
GKOS	1	2025-11-13	Aggregated
ALGN	2	2025-10-10	Aggregated
XRAY	1	2025-10-10	Aggregated
PEN	1	2025-07-23	Aggregated
EDAP	2	2025-04-04	Aggregated
PRCT	1	2024-11-14	Aggregated
PRCTPROCEPT BIOROBOTICS CORP	2	2024-11-14	Aggregated
GKOSGLAUKOS CORPORATION	2	2024-05-06	Aggregated
PROF	1	2023-03-21	Aggregated
PROFPROFOUND MEDICAL CORP	2	2023-03-21	Aggregated
EDAPEDAP TMS S.A. - ADR	2	2022-11-01	Aggregated

Methodology differs by source. Track records are aggregated from multiple sources; scoring methodology and scales differ by source and values are not directly comparable. Coverage is sourced from publicly-aggregated analyst activity. Past performance does not guarantee future results. Not investment advice.